IP Library › Patent Application 10553703
Patent Application
App. No. 10/553,703

Hla-A2 Tumor Associated Antigen Peptides and Compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/553,703
Abstract

A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.

Claims (179)

1 - 14 . (canceled)

15 . A composition comprising at least three peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

16 . A composition according to claim 15 , further comprising a fourth peptide, wherein said fourth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

17 . A composition according to claim 16 , further comprising a fifth peptide, wherein said fifth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

18 . A composition according to claim 17 , further comprising a sixth peptide, wherein said sixth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

19 . A composition according to claim 18 , further comprising a seventh peptide, wherein said seventh peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

20 . A composition according to claim 19 , further comprising a eighth peptide, wherein said eighth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

21 . A composition according to claim 20 , further comprising a ninth peptide, wherein said ninth peptide is less than 15 amino acid residues in length and comprises a cytotoxic T lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

22 . A composition according to claim 15 , further comprising an additional peptide, wherein said additional peptide is less than 25 amino acid residues in length and comprises an helper T lymphocyte (HTL) epitope.

23 . A composition according to claim 22 , wherein said additional peptide is a PanDR binding peptide.

24 . A composition according to claim 23 , wherein said Pan DR binding peptide comprises the amino acid sequence aKXVAAWTLKAAa (SEQ ID NO:1).

25 . A composition according to claim 15 , further comprising a liposome.

26 . A composition according to claim 15 , further comprising a lipid.

27 . A composition according to claim 15 , further comprising an antigen presenting cell.

28 . A composition according to claim 27 , wherein said antigen presenting cell is a dendritic cell.

29 . A composition according to claim 15 , further comprising a pharmaceutical excipient.

30 . A composition according to claim 29 , wherein said pharmaceutical excipient is an adjuvant.

31 . A composition according to claim 30 , wherein said adjuvant is a mineral oil adjuvant.

32 . An isolated nucleic acid encoding at least three peptides, wherein each of said three peptides is less than 15 amino acid residues in length and comprises a cytotoxic T-cell lymphocyte (CTL) epitope and/or analog selected from the group consisting of:

RLLQETELV,

(SEQ ID NO:2)

YLQLVFGIEV,

(SEQ ID NO:3)

LLTFWNPPV,

(SEQ ID NO:4)

SMPPPGTRV,

(SEQ ID NO:5)

KLBPVQLWV,

(SEQ ID NO:6)

KVFGSLAFV,

(SEQ ID NO:7)

YLSGADLNL,

(SEQ ID NO:8)

IMIGHLVGV,

(SEQ ID NO:9)

and

KVAEIVHFL.

(SEQ ID NO:10)

33 . A method for the treatment or prevention of cancer, said method comprising administering the composition of claim 15 to a patient in need thereof.

34 . A method according to claim 33 , wherein said treatment delays the recurrence of cancer following surgery, radiation therapy or chemotherapy.

35 . A method according to claim 33 , wherein said treatment prevents the metastasis of a primary tumor.

36 . A method according to claim 33 , wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.

37 . A method for the treatment or prevention of cancer, said method comprising administering the nucleic acid of claim 32 to a patient in need thereof.

38 . A method according to claim 37 , wherein said treatment delays the recurrence of cancer following surgery, chemotherapy or radiation.

39 . A method according to claim 37 , wherein said treatment prevents the metastasis of a primary tumor.

40 . A method according to claim 37 , wherein said cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, non-small cell lung cancer, ovarian cancer, gastric cancer, melanoma and a cancer of the head and/or neck.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: IDM PHARMA, INC.
To: BIOTECH SYNERGY, INC.
Reel/Frame 033453/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: BIOTECH SYNERGY, INC.
To: OSE PHARMA INTERNATIONAL SA
Reel/Frame 033453/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2011
From: IDM PHARMA, INC.
To: BIOTECH SYNERGY, INC.
Reel/Frame 026765/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2007
From: FIKES, JOHN D.; ISHIOKA, GLENN; SETTE, ALESSANDRO; CHESNUT, ROBERT W.
To: IDM PHARMA, INC.
Reel/Frame 019314/0522 →